



CONSUMER HEALTH

January 18, 2023

The Honorable Ayanna Pressley  
U.S. House of Representatives  
Washington, D.C. 20515

The Honorable Elizabeth Warren  
U.S. Senate  
Washington, D.C. 20510

The Honorable Lori Trahan  
U.S. House of Representatives  
Washington, D.C. 20515

The Honorable Katherine Clark  
U.S. House of Representatives  
Washington, D.C. 20515

Dear Representative Pressley, Senator Warren, Representative Trahan, and Representative Clark,

Thank you for your inquiry related to the availability of Infant and Children's TYLENOL<sup>®</sup> and MOTRIN<sup>®</sup>. We share your dedication to the constituents you serve, and we appreciate the opportunity to share more background with you on this important topic. We are doing everything we can to meet the needs of parents and caregivers in your district and across the country, and there has been no matter more important to us than this.

As a company dedicated to consumer health care, we are fully committed to ensuring people, parents, and caregivers have access to the products they need; and, as you noted in your letter, this cold and flu season has been especially challenging given the high incidences of flu cases, combined with respiratory syncytial virus (RSV) and Covid-19. The resulting "triple-demic" has led to unprecedented demand for pain relievers and fever reducers such as Infant and Children's TYLENOL<sup>®</sup> and MOTRIN<sup>®</sup>, as well as other cold and flu products.

Based on early forecasts, we maximized production of Infant and Children's TYLENOL<sup>®</sup> and MOTRIN<sup>®</sup> well in advance of the cold and flu season.<sup>1</sup> In fact, our production facilities have been running 24 hours a day, 7 days a week since April 2022 resulting in record level output and a 50% increase in production year-over-year. To boost supply further, given the unprecedented demand we have seen recently, we will be activating additional capacity at a third-party which should supplement current outputs.

To ensure we are there for our consumers during this difficult time, we have also updated our Consumer Care Center (CCC) protocols to help families find product in their local area and, in some cases, ship product directly to consumers when it is difficult to locate. Our CCC also provides information to parents about the correct dosage information for children for Regular Strength (indicated for use for children six years and older, although parents and caregivers of young children should always ask their doctor before using any adult Tylenol products if they have any concerns). Our CCC operators are accessible by telephone, email, or social media. For more information, please refer to [www.tylenol/contact-us](http://www.tylenol/contact-us).

We are committed to ongoing and transparent communication, and have continued to partner with healthcare providers, hospital associations, pharmacists, retailers, government officials and regulators because we know this situation requires all of us to work together. Each stakeholder

---

<sup>1</sup> We forecast consumer demand in various ways. This includes point of sale data as well as using industry standard fever incidence forecast data. While the model anticipated higher incidences of the flu, variants of Covid-19, and RSV, the increase in incidences of all three towards the end of 2022 went beyond projections and presented a challenge for the health care system writ large - from the availability of pediatric medicines to the availability of hospital beds.


comes to this issue with a different perspective, but we all have a common goal to combat the impacts stemming from the “triple-demic”.

Key among these stakeholders is the U.S. Food and Drug Administration (FDA). We have been in regular communication with the FDA leading up to and throughout this cold and flu season regarding our supply of Infant and Children’s TYLENOL® and MOTRIN®. As demand increased with incidences of flu, RSV, and Covid-19 on the rise, we began providing weekly updates to the FDA starting December 7, 2022 to ensure our organizations are working closely to address this dynamic situation.

We take this matter very seriously and share your concern that parents, families, and caregivers – and most of all infants and children – may not have ready access to the products they need. Fortunately, the most recent epidemiological insights show a decrease in incidences of fever over the last three weeks, which should be a positive development for future retail inventory recovery. That being said, our team of dedicated consumer health professionals will continue working hard to boost supply and be there for all those we serve.

If you have any other questions or concerns, please contact Sami Naim, Head of Government Affairs for North America, at [snaim2@its.jnj.com](mailto:snaim2@its.jnj.com).

Sincerely,

A handwritten signature in black ink, appearing to read "Kathy Widmer". The signature is fluid and cursive, with a large initial "K" and "W".

Kathy Widmer  
Company Group Chairman, North America and LATAM  
Johnson & Johnson Consumer Health